NxStage Reports Record Fourth Quarter and Full-Year 2015 Revenue
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq reaches record high close, AI stocks rally
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Piper Jaffray Cuts Price Target on Nxstage Medical (NXTM) Following Mixed 4Q Results
February 11, 2016 9:23 AM ESTPiper Jaffray maintained an Overweight rating on NxStage Medical (NASDAQ: NXTM), and cut the price target to $23.00 (from $24.00), following the company's 4Q earnings report. Revenue exceeded expectations, while net loss was in-line with Street estimates. 2016 revenue guidance was lower than Street estimates due to a $20M... More
Nxstage Medical (NXTM) Reports In-Line Q4 EPS; Issues Light FY16 Revenue Outlook
February 10, 2016 8:07 AM ESTNxstage Medical (NASDAQ: NXTM) reported Q4 EPS of ($0.04), in-line with the analyst estimate of ($0.04). Revenue for the quarter came in at $89.8 million versus the consensus estimate of $86.83 million.
GUIDANCE:
Nxstage Medical sees Q1 2016 revenue of $87-89 million, versus the consensus... More
